IN2014DN03206A - - Google Patents
Info
- Publication number
- IN2014DN03206A IN2014DN03206A IN3206DEN2014A IN2014DN03206A IN 2014DN03206 A IN2014DN03206 A IN 2014DN03206A IN 3206DEN2014 A IN3206DEN2014 A IN 3206DEN2014A IN 2014DN03206 A IN2014DN03206 A IN 2014DN03206A
- Authority
- IN
- India
- Prior art keywords
- bace
- alzheimer
- variables
- disease
- combinations
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
- C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Abstract
The invention relates to novel oxazine derivatives of formula (I) and pharmaceutically acceptable salts thereof in which all of the variables are as defined in the specification pharmaceutical compositions thereof combinations thereof and their use as medicaments particularly for the treatment of Alzheimer s Disease or diabetes via inhibition of BACE 1 or BACE 2.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161546836P | 2011-10-13 | 2011-10-13 | |
US201261695329P | 2012-08-31 | 2012-08-31 | |
PCT/IB2012/055521 WO2013054291A1 (en) | 2011-10-13 | 2012-10-11 | Novel oxazine derivatives and their use in the treatment of disease |
Publications (1)
Publication Number | Publication Date |
---|---|
IN2014DN03206A true IN2014DN03206A (en) | 2015-05-22 |
Family
ID=47258045
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IN3206DEN2014 IN2014DN03206A (en) | 2011-10-13 | 2012-10-11 |
Country Status (12)
Country | Link |
---|---|
US (1) | US9284284B2 (en) |
EP (1) | EP2766358B1 (en) |
JP (1) | JP2014532066A (en) |
KR (1) | KR20140084146A (en) |
CN (1) | CN103987710A (en) |
AU (1) | AU2012322329A1 (en) |
BR (1) | BR112014008686A2 (en) |
CA (1) | CA2851445A1 (en) |
EA (1) | EA201490774A1 (en) |
IN (1) | IN2014DN03206A (en) |
MX (1) | MX2014004479A (en) |
WO (1) | WO2013054291A1 (en) |
Families Citing this family (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR077328A1 (en) | 2009-07-24 | 2011-08-17 | Novartis Ag | DERIVATIVES OF OXAZINE AND ITS USE IN THE TREATMENT OF NEUROLOGICAL DISORDERS |
JP5711813B2 (en) | 2010-06-09 | 2015-05-07 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプJanssen Pharmaceutica Naamloze Vennootschap | 5,6-Dihydro-2H- [1,4] oxazin-3-yl-amine derivatives useful as inhibitors of β-secretase (BACE) |
JP5834091B2 (en) | 2010-12-22 | 2015-12-16 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプJanssen Pharmaceutica Naamloze Vennootschap | 5,6-Dihydro-imidazo [1,2-a] pyrazin-8-ylamine derivatives useful as inhibitors of beta-secretase (BACE) |
WO2012095469A1 (en) | 2011-01-13 | 2012-07-19 | Novartis Ag | Novel heterocyclic derivatives and their use in the treatment of neurological disorders |
PL2681219T3 (en) | 2011-03-01 | 2016-03-31 | Janssen Pharmaceutica Nv | 6,7-dihydro-pyrazolo[1,5-a]pyrazin-4-ylamine derivatives useful as inhibitors of beta-secretase (bace) |
WO2012120023A1 (en) | 2011-03-09 | 2012-09-13 | Janssen Pharmaceutica Nv | 3,4-DIHYDRO-PYRROLO[1,2-a]PYRAZIN-1-YLAMINE DERIVATIVES USEFUL AS INHIBITORS OF BETA-SECRETASE (BACE) |
AU2012347396B2 (en) * | 2011-12-06 | 2017-02-16 | Janssen Pharmaceutica Nv | 5-(3-aminophenyl)-5-alkyl-5,6-dihydro-2H-[1,4]oxazin-3-amine derivatives |
MX366855B (en) | 2013-03-01 | 2019-07-26 | Amgen Inc | Perfluorinated 5,6-dihydro-4h-1,3-oxazin-2-amine compounds as beta-secretase inhibitors and methods of use. |
SG11201507196WA (en) | 2013-03-08 | 2015-10-29 | Amgen Inc | Perfluorinated cyclopropyl fused 1,3-oxazin-2-amine compounds as beta-secretase inhibitors and methods of use |
CA2912156C (en) | 2013-06-12 | 2021-07-20 | Janssen Pharmaceutica Nv | 4-amino-6-phenyl-5,6-dihydroimidazo[1,5-a]pyrazin-3(2h)-one derivatives as inhibitors of beta-secretase (bace) |
ES2721073T3 (en) | 2013-06-12 | 2019-07-26 | Janssen Pharmaceutica Nv | 4-Amino-6-phenyl-6,7-dihydro [1,2,3] triazolo [1,5 a] pyrazine derivatives as beta-secretase inhibitors (BACE) |
AU2014280124B2 (en) | 2013-06-12 | 2018-11-01 | Janssen Pharmaceutica Nv | 4-amino-6-phenyl-5,6-dihydroimidazo[1,5-a]pyrazine derivatives as inhibitors of beta-secretase (BACE) |
CA2957544C (en) | 2014-08-08 | 2023-01-24 | Amgen Inc. | Cyclopropyl fused thiazin-2-amine compounds as beta-secretase inhibitors and methods of use |
JP2017538753A (en) | 2014-12-18 | 2017-12-28 | ヤンセン ファーマシューティカ エヌ.ベー. | Β-secretase inhibitors of 2,3,4,5-tetrahydropyridin-6-amine and 3,4-dihydro-2H-pyrrol-5-amine compounds |
US20170107216A1 (en) | 2015-10-19 | 2017-04-20 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
RS63762B1 (en) | 2015-11-19 | 2022-12-30 | Incyte Corp | Heterocyclic compounds as immunomodulators |
KR20180100585A (en) | 2015-12-22 | 2018-09-11 | 인사이트 코포레이션 | Heterocyclic compounds as immunomodulators |
ES2906460T3 (en) | 2016-05-06 | 2022-04-18 | Incyte Corp | Heterocyclic compounds as immunomodulators |
TW201808902A (en) | 2016-05-26 | 2018-03-16 | 美商英塞特公司 | Heterocyclic compounds as immunomodulators |
AU2017281285C1 (en) | 2016-06-20 | 2022-05-12 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
WO2018013789A1 (en) | 2016-07-14 | 2018-01-18 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
JOP20190003A1 (en) * | 2016-07-19 | 2019-01-10 | Novartis Ag | An Oxazine Derivative for Use in the Prevention of Alzheimer?s disease in at Risk Patients |
US20180057486A1 (en) | 2016-08-29 | 2018-03-01 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
WO2018056664A2 (en) * | 2016-09-22 | 2018-03-29 | 아주대학교산학협력단 | Composition for obesity treatment comprising liquid-phase plasma |
MA47120A (en) | 2016-12-22 | 2021-04-28 | Incyte Corp | PYRIDINE DERIVATIVES USED AS IMMUNOMODULATORS |
US20180179202A1 (en) * | 2016-12-22 | 2018-06-28 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
PE20191532A1 (en) | 2016-12-22 | 2019-10-23 | Incyte Corp | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS |
EP3558989B1 (en) | 2016-12-22 | 2021-04-14 | Incyte Corporation | Triazolo[1,5-a]pyridine derivatives as immunomodulators |
BR112020022936A2 (en) | 2018-05-11 | 2021-02-02 | Incyte Corporation | tetrahydro-imidazo [4,5-c] pyridine derivatives as pd-l1 immunomodulators |
WO2021030162A1 (en) | 2019-08-09 | 2021-02-18 | Incyte Corporation | Salts of a pd-1/pd-l1 inhibitor |
WO2021096849A1 (en) | 2019-11-11 | 2021-05-20 | Incyte Corporation | Salts and crystalline forms of a pd-1/pd-l1 inhibitor |
CN110950865B (en) * | 2019-12-16 | 2022-05-17 | 诚达药业股份有限公司 | Synthetic method of medical intermediate 8-chloro-1, 7-naphthyridine-3-formaldehyde |
CN112250580A (en) * | 2020-10-28 | 2021-01-22 | 上海昂卓新材料科技有限公司 | Preparation method of 2-nitro-2-substituted phenyl propane-1, 3-diol |
US11780836B2 (en) | 2020-11-06 | 2023-10-10 | Incyte Corporation | Process of preparing a PD-1/PD-L1 inhibitor |
WO2022099075A1 (en) | 2020-11-06 | 2022-05-12 | Incyte Corporation | Crystalline form of a pd-1/pd-l1 inhibitor |
IL302590A (en) | 2020-11-06 | 2023-07-01 | Incyte Corp | Process for making a pd-1/pd-l1 inhibitor and salts and crystalline forms thereof |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW200303742A (en) | 2001-11-21 | 2003-09-16 | Novartis Ag | Organic compounds |
CA2514733A1 (en) | 2003-02-28 | 2004-09-16 | Transform Pharmaceuticals, Inc. | Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen |
ATE442365T1 (en) | 2003-05-20 | 2009-09-15 | Novartis Pharma Gmbh | N-ACYL NITROGEN HETEROCYCLES AS LIGANDS OF PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS |
JP2008531596A (en) | 2005-02-25 | 2008-08-14 | ライジェル ファーマシューティカルズ, インコーポレイテッド | Benzisothiazole useful for treating or preventing HCV infection |
ES2476027T3 (en) * | 2005-10-25 | 2014-07-11 | Shionogi & Co., Ltd. | Aminodihydrotriazine derivatives |
EP2151435A4 (en) * | 2007-04-24 | 2011-09-14 | Shionogi & Co | Pharmaceutical composition for treatment of alzheimer's disease |
WO2010063718A1 (en) | 2008-12-02 | 2010-06-10 | ETH Zürich | Screening assay for metabolic disease therapeuticals |
AR077328A1 (en) * | 2009-07-24 | 2011-08-17 | Novartis Ag | DERIVATIVES OF OXAZINE AND ITS USE IN THE TREATMENT OF NEUROLOGICAL DISORDERS |
US8188079B2 (en) * | 2009-08-19 | 2012-05-29 | Hoffman-La Roche Inc. | 3-amino-5-phenyl-5,6-dihydro-2H-[1,4]oxazines |
EP2500344A4 (en) * | 2009-11-13 | 2013-05-01 | Shionogi & Co | Aminothiazine or aminooxazine derivative having amino linker |
US8673894B2 (en) | 2010-05-07 | 2014-03-18 | Hoffmann-La Roche Inc. | 2,5,6,7-tetrahydro-[1,4]oxazepin-3-ylamine or 2,3,6,7-tetrahydro-[1,4]oxazepin-5-ylamine compounds |
JP5711813B2 (en) | 2010-06-09 | 2015-05-07 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプJanssen Pharmaceutica Naamloze Vennootschap | 5,6-Dihydro-2H- [1,4] oxazin-3-yl-amine derivatives useful as inhibitors of β-secretase (BACE) |
JP2014505688A (en) | 2011-01-12 | 2014-03-06 | ノバルティス アーゲー | Oxazine derivatives and their use in the treatment of neurological disorders |
US20140128385A1 (en) | 2011-01-13 | 2014-05-08 | Novartis Ag | Bace-2 inhibitors for the treatment of metabolic disorders |
WO2012095469A1 (en) | 2011-01-13 | 2012-07-19 | Novartis Ag | Novel heterocyclic derivatives and their use in the treatment of neurological disorders |
US9242943B2 (en) | 2011-01-18 | 2016-01-26 | Siena Biotech S.P.A. | 1,4 oxazines as BACE1 and/or BACE2 inhibitors |
US8399459B2 (en) | 2011-02-02 | 2013-03-19 | Hoffmann-La Roche Inc. | 1,4 oxazines as BACE1 and/or BACE2 inhibitors |
-
2012
- 2012-10-11 JP JP2014535212A patent/JP2014532066A/en active Pending
- 2012-10-11 CN CN201280060971.4A patent/CN103987710A/en active Pending
- 2012-10-11 IN IN3206DEN2014 patent/IN2014DN03206A/en unknown
- 2012-10-11 AU AU2012322329A patent/AU2012322329A1/en not_active Abandoned
- 2012-10-11 MX MX2014004479A patent/MX2014004479A/en unknown
- 2012-10-11 KR KR1020147012410A patent/KR20140084146A/en not_active Application Discontinuation
- 2012-10-11 CA CA2851445A patent/CA2851445A1/en not_active Abandoned
- 2012-10-11 US US14/350,938 patent/US9284284B2/en active Active
- 2012-10-11 BR BR112014008686A patent/BR112014008686A2/en not_active Application Discontinuation
- 2012-10-11 EP EP12791856.3A patent/EP2766358B1/en not_active Not-in-force
- 2012-10-11 EA EA201490774A patent/EA201490774A1/en unknown
- 2012-10-11 WO PCT/IB2012/055521 patent/WO2013054291A1/en active Application Filing
Also Published As
Publication number | Publication date |
---|---|
CN103987710A (en) | 2014-08-13 |
EA201490774A1 (en) | 2014-08-29 |
EP2766358A1 (en) | 2014-08-20 |
EP2766358B1 (en) | 2016-06-22 |
BR112014008686A2 (en) | 2017-04-25 |
AU2012322329A1 (en) | 2014-05-01 |
CA2851445A1 (en) | 2013-04-18 |
US20140256715A1 (en) | 2014-09-11 |
US9284284B2 (en) | 2016-03-15 |
WO2013054291A1 (en) | 2013-04-18 |
MX2014004479A (en) | 2014-08-01 |
KR20140084146A (en) | 2014-07-04 |
JP2014532066A (en) | 2014-12-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IN2014DN03206A (en) | ||
TN2014000062A1 (en) | 2 -amino-4 - (pyridin- 2 -yl) - 5, 6 -dihydro-4h- 1, 3 -oxazine derivatives and their use as bace-1 and/or bace - 2 inhibitors | |
TN2013000285A1 (en) | Novel heterocyclic derivatives and their use in the treatment of neurological disorders | |
MX2014000341A (en) | Novel trifluoromethyl-oxadiazole derivatives and their use in the treatment of disease. | |
MX2012001070A (en) | Oxazine derivatives and their use as bace inhibitors for the treatment of neurological disorders. | |
IN2012DN01233A (en) | ||
PH12015501385A1 (en) | Autotaxin inhibitors | |
MX343706B (en) | Novel heterocyclic derivatives. | |
EA201391029A1 (en) | OXAZIN DERIVATIVES AND THEIR APPLICATION IN THE TREATMENT OF NEUROLOGICAL DISORDERS | |
MX2014012695A (en) | Isoindolone derivatives. | |
PE20121617A1 (en) | OXAZINE DERIVATIVES AS BACE INHIBITORS | |
PH12014501514A1 (en) | New azetidine derivatives, pharmaceutical compositions and uses thereof | |
UA104489C2 (en) | Compounds for the treatment of dyslipidemia and related diseases | |
UA113538C2 (en) | FLUOROMETHYL-5,6-DIHYDRO-4H- $ 1,3] OXAZINES | |
IN2012DN02139A (en) | ||
MX2013008056A (en) | 1,4-oxazepines as bace1 and/or bace2 inhibitors. | |
WO2013040227A3 (en) | Therapeutic compounds | |
MY156302A (en) | COMPOUNDS, COMPOSITIONS AND METHODS FOR THE TREATMENT OF ß-AMYLOID DISEASES AND SYNUCLEINOPATHIES | |
NZ702254A (en) | 5-amino[1,4]thiazines as bace 1 inhibitors | |
UA117154C2 (en) | S1p3 antagonists | |
PH12015500012A1 (en) | Benzodioxole derivative and preparation method and use thereof | |
MX2013002208A (en) | Sulfonylpiperazine derivatives that interact with glucokinase regulatory protein for the treatment of diabetes. | |
MX2013003202A (en) | Oxadiazole inhibitors of leukotriene production. | |
GEP201606566B (en) | Isoxazolidine derivatives | |
MX2014000870A (en) | Pharmaceutical compositions comprising 4-bromo-n-(imidazolidin-2- ylidene)-1h-benzimidazol-5-amine for treating retinal diseases. |